Spectrum Pharmaceuticals, Inc.  

(Public, NASDAQ:SPPI)   Watch this stock  
Find more results for SPPI
-0.05 (-0.53%)
After Hours: 9.37 -0.03 (-0.32%)
Aug 18, 6:29PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.32 - 9.51
52 week 3.21 - 9.70
Open 9.36
Vol / Avg. 1.17M/978,127.00
Mkt cap 794.32M
P/E     -
Div/yield     -
EPS -0.99
Shares 84.50M
Beta 1.49
Inst. own 66%
Aug 24, 2017
Spectrum Pharmaceuticals Inc at Seaport Global Securities Southern California Investor Conference Add to calendar
Aug 3, 2017
Q2 2017 Spectrum Pharmaceuticals Inc Earnings Call
Jun 28, 2017
Spectrum Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Jun 6, 2017
Spectrum Pharmaceuticals Inc at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -59.67% -46.78%
Operating margin -53.13% -42.08%
EBITD margin - -24.02%
Return on average assets -20.56% -16.16%
Return on average equity -39.46% -30.53%
Employees 227 -
CDP Score - -


11500 S Eastern Ave Ste 240
HENDERSON, NV 89052-5576
United States - Map
+1-702-8356300 (Phone)
+1-702-2607405 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.

Officers and directors

Rajesh C. Shrotriya M.D. Chairman of the Board, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Joseph W. Turgeon President, Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Kurt A. Gustafson Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Luigi Lenaz M.D. Lead Independent Director
Age: 74
Bio & Compensation  - Reuters
Gilles R. Gagnon Director
Age: 61
Bio & Compensation  - Reuters
Raymond Wayne Cohen Independent Director
Age: 57
Bio & Compensation  - Reuters
Stuart M. Krassner Independent Director
Age: 79
Bio & Compensation  - Reuters
Anthony E. Maida III, Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters